The good news is that AstraZeneca is a good stock,with or without a COVID-19 vaccine. The company's stable business, growing revenue and earnings, and strong catalog of drugs craft a strong buy case. Shares of AstraZeneca gained 31.2% last year, higher than the market's growth of 29%.